Cochlear share price on watch after COVID-19 profit collapse

The Cochlear Limited (ASX:COH) share price will be on watch today after reporting a collapse in profits because of the COVI9-19 pandemic…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price will be on watch on Tuesday following the release of its full year results for FY 2020.

How did Cochlear perform in FY 2020?

For the 12 months ended 30 June 2020, the hearing solutions company reported sales revenue of $1,352.3 million, which represents a 6% decline on a reported basis or 11% in constant currency. This revenue comprises Cochlear implants revenue of $817.9 million (down 3%), Services revenue of $395.5 million (down 7%), and Acoustics revenue of $138.9 million (down 20%).

Management advised that this decline was caused by difficult trading conditions in the second half because of COVID‐19‐related surgery deferrals. Cochlear implant unit sales fell 7% over the 12 months, having been up 13% during the first half.

On the bottom line Cochlear reported an underlying net profit after tax of US$153.8 million, which was down 42% year on year. This follows a collapse in its profits during the second half because of the aforementioned surgery deferrals. Second half profit fell 84% on the prior corresponding period.

On a reported basis, Cochlear recorded a net loss of $238.3 million. This includes $416.3 million in patent litigation expenses and $24.2 million in innovation fund gains after‐tax.

In light of the above, the company has unsurprisingly decided against declaring a final dividend in FY 2020.

Trading update.

Management advised that while elective surgeries have resumed, there is still a risk that second waves could result in new restrictions, complicating recovery plans and timing.

It also recognises that the surgeries currently occurring, particularly for adults and seniors, include a catch up of delayed surgeries from March to May. And while the majority of clinics have re‐opened, many are still running below capacity as they recommence operations carefully and follow social distancing disciplines.

As a result, the company expects there to be some impact on the number of patient assessments for cochlear and acoustic implants until clinic throughput normalises.

Nevertheless, the company's direct‐to‐consumer activities have been aimed at providing additional support to candidates, and potential candidates. It hopes these activities may assist in more quickly rebuilding the candidate pipeline once things normalise.

Outlook.

Due to the uncertain timing of a global recovery from the pandemic, management acknowledges that it cannot reliably estimate its FY 2021 revenues. As a result, it will not be providing guidance at this stage.

However, it intends to provide a trading update with its annual general meeting in late Octover.

Until then, the company "will be focused on market growth activities and strengthening our competitive position, while continuing to limit non‐essential spending until we have greater confidence in the outlook. There are a number of cost base considerations for FY21, which may be adapted if trading conditions materially change."

Looking further ahead, management is confident on the future prospects of the company.

It commented: "As we look to the future, we remain confident about the opportunity to grow our markets. There remains a significant, unmet and addressable clinical need for cochlear and acoustic implants that is expected to continue to underpin the long‐term sustainable growth of the business."

The company also notes that the arrival of telehealth solutions during the pandemic could be a big positive for its business.

"The pandemic has also driven the rapid adoption of telehealth and telemedicine which may lead to faster than expected structural changes in healthcare delivery. We experienced this first hand with the FDA fast‐tracking the approval of our Remote Check solution in the US."

"We have been investing in connected care solutions for many years and believe they provide the opportunity to open up access to our products and optimise outcomes for recipients by transforming the care model while delivering efficiencies to clinics," it added.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising
Share Market News

5 things to watch on the ASX 200 on Friday

A good finish to the week is expected for Aussie investors.

Read more »

A man has computer-generated images rushing through his head indicating an AI (Artificial Intelligence) concept of a communication network.
Technology Shares

ASX investors are obsessed with Nvidia shares! Here's why

The global chipmaker reported a 94% increase in annual revenue in the third quarter.

Read more »

A man wearing a red jacket and mountain hiking clothes stands at the top of a mountain peak and looks out over countless mountain ranges.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another disappointing day for ASX investors this Thursday.

Read more »

two racing cars battle to take first place on a formula one track with one tailing the the leader and looking to overtake the car.
Opinions

Down 21% in 2024. This ASX 300 stock looks like a money-making monster

Profits are expected to plunge, but the future could still be bright.

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
52-Week Lows

Down 68% from highs, this ASX 200 stock just hit a 4-year low. Time to pounce?

Is this beaten down stock a buy? Let's see what one leading broker is saying.

Read more »

two men smiling with a laptop in front of them, symbolising a rising share price.
Share Gainers

Why Pinnacle, PWR, Race Oncology, and Vulcan shares are flying today

These shares are having a good session on Thursday. But why?

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Accent, Sayona Mining, Web Travel, and Weebit Nano shares are dropping today

These shares are having a tough time on Thursday. Why are they being sold off?

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Share Market News

Insider buying alert: 3 ASX 200 shares directors are snapping up right now

Directors in some of Australia's blue-chip businesses aren't shying away from the market.

Read more »